Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
G Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri et autres
Abstract Introduction: Preclinical data indicates that the investigational ROS1 TKI zidesamtinib offers improved potency against ROS1, including ROS1 G2032R resistance mutation, brain penetrance and TRK selectivity over FDA-approved dual TRK/ROS1 TKIs repotrectinib and taletrectinib. Maximizing ROS1 activity in the clinical setting, including …
ca, us, fr, it, jp, au, be, nl, tw, sg, es, Afrique du Sud, kr, gb, de (code pays fourni par la source)